Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;47(2):248-254.
doi: 10.1007/s11239-019-01805-0.

Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism

Affiliations

Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism

Joanna Żuk et al. J Thromb Thrombolysis. 2019 Feb.

Abstract

Associations of Raynaud's phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occurrence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort study we enrolled 360 patients free of known autoimmune disease. D-dimer, von Willebrand factor (vWF), plasma clot permeability (Ks), clot lysis time (CLT) along with fibrinolysis activators and inhibitors were determined at least 3 months since the VTE event. The presence/absence of RP was diagnosed at least 6 months before VTE. Primary RP occurred in 57 subjects (17%) with a 3.6-fold higher prevalence among women. Patients with RP had 11% higher fibrinogen, 16% higher vWF, 5% lower Ks, and 10% longer CLT (all p < 0.05). Females with RP (21%) had 6.6% lower Ks, 11.2% longer CLT, and 18.5% higher vWF (all p < 0.05) compared with men. CLT was predicted by PAI-1 and vWF levels. Regression analysis showed that RP was a predictor of prolonged CLT in the whole patient group (OR 3.46, 95% CI 1.92-6.24) and in women following VTE (OR 2.75, 95% CI 1.31-5.78). Primary RP patients tend to form denser plasma fibrin clots displaying impaired lysability and increased endothelial damage. RP might be a novel risk factor for VTE, especially in women.

Keywords: Fibrin; Fibrinolysis; Raynaud phenomenon; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Receiver operating characteristic (ROC) curves for Ks (a) and CLT (b). a Using RAYNAUD = '1′ to be the positive level, AUC 0.59, 95% CI 0.51–0.67; b using RAYNAUD = ‘1’ to be the positive level, AUC 0.65, 95% CI 0.57–0.73

Similar articles

Cited by

References

    1. Wigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med. 2002;347:1001–1008. doi: 10.1056/NEJMcp013013. - DOI - PubMed
    1. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44:587–596. doi: 10.1093/rheumatology/keh552. - DOI - PubMed
    1. Bakst R, Merola JF, Franks AG, Jr, et al. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol. 2008;59:633–653. doi: 10.1016/j.jaad.2008.06.004. - DOI - PubMed
    1. Linnemann M, Erbe M. Raynaud‘s phenomenon—assessment and differential diagnoses. VASA. 2015;44:166–177. doi: 10.1024/0301-1526/a000426. - DOI - PubMed
    1. Prete M, Fatone MC, Favoino E, Perosa F. Raynaud’s phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014;13:655–667. doi: 10.1016/j.autrev.2013.12.001. - DOI - PubMed

MeSH terms